Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Activity and safety of nivolumab, an anti-PD-1 immune che... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
0
Authors
Naiyer Rizvi
33 more
Naiyer Rizvi
•
Pierre Souquet
31 more
•
Suresh Ramalingam
Published
February 20, 2015
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Physics
Cancer Oncology
Medicine
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(15)70054-9
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Physics
Cancer Oncology
Medicine
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(15)70054-9
Other Formats
PDF
